Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2014
At a glance
- Drugs Ramucirumab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 14 Jul 2012 Additional trial location (United Kingdom) identified as reported by European Clinical Trials Database.
- 14 Jul 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-006713-16).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History